Ensign invites current and prospective investors to tune into a live webcast to be held the following day, Tuesday, November 4, 2025, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time), during which ...
Interim CEO Anders Lonning-Skovgaard - Executive Vice President, CFO Kristine Husted Munk - Senior Director, Investor Relations Simone Dyrby Helvind - Senior Manager, Investor Relations Webcast For ...
The Living Brain Project (LBP) is a collaborative research initiative led by the Icahn School of Medicine at Mount Sinai. Its mission is to generate, analyze, and openly share the world’s first ...
Pritelivir Phase 2 results supported FDA Breakthrough Therapy Designation and informed the pivotal study design, which recently culminated in positive Phase 3 topline results Phase 1 results for ...
J-Star (through its YMA subsidiary) has manufactured racquets for several leading global brands and recently launched its first company owned pickleball paddle, Horizon. Visit ymapaddles.com for more ...
The tender offer will expire at 5:00 p.m. ET on Tuesday, November 18, 2025, unless extended or earlier terminated. The full terms, conditions and other details of the tender offer are set forth in the ...
This follow-on investment builds on Angelini Ventures' co-lead participation in CoMind's 2023 Series A funding round of $27 million alongside Octopus Ventures and underscores Angelini Ventures' ...
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
During the past few months, Replimune has been working to address agency feedback. Additional information, data and analyses were included in the resubmission which will be part of the BLA review. The ...
Additionally, EMPAVELI continued to stabilize kidney function as measured by estimated glomerular filtration rate (eGFR), a key measure of kidney function. EMPAVELI showed favorable safety and ...
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National ...
RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital ...
Jefferies, Leerink Partners, Morgan Stanley and Cantor are acting as joint book-running managers for the proposed offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback